Damora Therapeutics reported cash from operations of -$17.20M and free cash flow of -$17.20M for the quarter ended Sep 2026. This cash flow statement covers 29 quarters of results from Sep 2019 through Sep 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow StatementCash Flow | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 | Sep2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||||||
| Net Income | -13.46M | -16.94M | -16.90M | -13.70M | -14.02M | -13.00M | -10.70M | -8.10M | -6.45M | -5.50M | -5.30M | -3.90M | -6.74M | -2.53M | -3.40M | -3.10M | -200.74M | -27.80M | -31.20M | -32.00M | |||||||||
| Depreciation and DepletionDep. & Depletion | 0.01M | 0.01M | 0.01M | 0.01M | 0.02M | 0.02M | 0.02M | 0.21M | 0.05M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | |||||||||
| Depreciation, Depletion & Amortization | |||||||||||||||||||||||||||||
| Depreciation & Amortization (CF)Dep. & Amort. | 0.01M | 0.01M | 0.01M | 0.01M | 0.02M | 0.02M | 0.02M | 0.21M | 0.05M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | 0.01M | |||||||||
| Share-based CompensationStock Comp. | 1.24M | 1.40M | 1.42M | 1.40M | 1.35M | 1.43M | 1.44M | 1.46M | 1.09M | 1.36M | 0.89M | 0.68M | 0.31M | 0.18M | 0.17M | 0.16M | 0.48M | 8.12M | 10.69M | 9.88M | |||||||||
| Gains from Sales and DivestituresGains Divest | 0.75M | ||||||||||||||||||||||||||||
| Other non-cash itemsOther Non-Cash | 0.26M | ||||||||||||||||||||||||||||
| Change in Working Capital | |||||||||||||||||||||||||||||
| Change in Account PayablesChange Payables | 2.60M | ||||||||||||||||||||||||||||
| Change in Accrued ExpensesChange Accrued Exp. | 3.95M | ||||||||||||||||||||||||||||
| Change in TaxesChange Taxes | |||||||||||||||||||||||||||||
| Change in Other Operating AssetsOther Assets Change | 0.20M | ||||||||||||||||||||||||||||
| Change in Other Operating LiabilitiesOther Liabilities Change | 0.01M | ||||||||||||||||||||||||||||
| Other Working Capital ChangesOther WC Changes | -0.20M | ||||||||||||||||||||||||||||
| Cash from OperationsCash from Ops. | -17.20M | ||||||||||||||||||||||||||||
| Investing Activities | |||||||||||||||||||||||||||||
| Capital ExpendituresCapex | 0.00M | 0.04M | -0.03M | 0.14M | 0.04M | ||||||||||||||||||||||||
| Change in Property, Plant and EquipmentChange in PP&E | 0.00M | -0.04M | 0.03M | -0.14M | -0.04M | ||||||||||||||||||||||||
| Purchase of InvestmentsInvestments Purchased | 26.39M | 14.27M | 4.21M | 12.75M | 9.24M | 3.94M | |||||||||||||||||||||||
| Sale and Maturity of InvestmentsInvestments Sold | 14.41M | 16.22M | 14.19M | 8.45M | 18.58M | 14.13M | 12.33M | 12.23M | 9.50M | 5.65M | 6.00M | ||||||||||||||||||
| Cash from Investing ActivitiesCash from Investing | 14.41M | -10.21M | -0.05M | 8.31M | 14.33M | 1.37M | 3.09M | 8.29M | 9.58M | 5.65M | 6.00M | ||||||||||||||||||
| Financing Activities | |||||||||||||||||||||||||||||
| Change in Capital Stock | |||||||||||||||||||||||||||||
| Common Stock IssuedStock Issued | 5.35M | ||||||||||||||||||||||||||||
| Net Shares Issued and RepurchasedNet Shares Issued | 5.12M | ||||||||||||||||||||||||||||
| Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued | |||||||||||||||||||||||||||||
| Net Equity Issued and RepurchasedNet Equity Issued | 5.12M | ||||||||||||||||||||||||||||
| Shares Repurchased | 0.23M | ||||||||||||||||||||||||||||
| Other financing activities (as filed) | |||||||||||||||||||||||||||||
| Cash from Financing ActivitiesCash from Financing | 5.12M | ||||||||||||||||||||||||||||
| Additional items | |||||||||||||||||||||||||||||
| Exchange Rate EffectFX Effect | 0.01M | ||||||||||||||||||||||||||||
| Change in Cash | -190.87M | ||||||||||||||||||||||||||||
| Ending Cash Balance | 349.66M | ||||||||||||||||||||||||||||
| Free Cash FlowFCF | -17.20M | ||||||||||||||||||||||||||||
| Net Cash FlowNCF | -12.08M | ||||||||||||||||||||||||||||
| Income Taxes PaidTaxes Paid | 0.00M | 0.00M |
Pull Damora Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=DMRA&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "DMRA", "statement": "CF", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=DMRA&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();